Additionally, the MGMT promoter methylation is prognostic and played a powerful predictor of temozolomide sensitivity in gliomas,2 we further reanalyze the relationship between riskscore and MGMT promoter methylation and found that the higher riskscore are enriched in the MGMT promoter un‐methylated group in both datasets (Figure 2B,C). The gene discussed is MGMT; the disease is glioma.